Liver and Bile

N Engl J Med. 2024;390(6):497–509

Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators

A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis


Background: Non-alcoholic steatohepatitis (NASH) is a progressive liver disease with no approved treatment. Resmetirom is an oral, liver-directed, thyroid hormone receptor β-selective agonist in development for the treatment of NASH with liver fibrosis.
Methods: The authors are conducting an ongoing phase 3 trial involving adults with biopsy-confirmed NASH and a fibrosis stage of F1B, F2, or F3 (stages range from F0 [no fibrosis] to F4 [cirrhosis]). Patients were randomly assigned in a 1:1:1 ratio to receive once-daily resmetirom at a dose of 80 mg or 100 mg or placebo. The 2 primary end points at week 52 were NASH resolution (including a reduction in the non-alcoholic fatty liver disease [NAFLD] activity score [NAS] by ≥ 2 points; scores range from 0–8, with higher scores indicating more severe disease) with no worsening of fibrosis, and an improvement (reduction) in fibrosis by at least 1 stage with no worsening of the NAS.
Results: Overall, 966 patients formed the primary analysis population (322 in the 80-mg resmetirom group, 323 in the 100-mg resmetirom group, and 321 in the placebo group). NASH resolution with no worsening of fibrosis was achieved in 25.9% of the patients in the 80-mg resmetirom group and 29.9% of those in the 100-mg resmetirom group, as compared with 9.7% of those in the placebo group (p < 0.001 for both comparisons with placebo). Fibrosis improvement by at least 1 stage with no worsening of the NAS was achieved in 24.2% of the patients in the 80-mg resmetirom group and 25.9% of those in the 100-mg resmetirom group, as compared with 14.2% of those in the placebo group (p < 0.001 for both comparisons with placebo). The change in low-density lipoprotein cholesterol levels from baseline to week 24 was -13.6% in the 80-mg resmetirom group and -16.3% in the 100-mg resmetirom group, as compared with 0.1% in the placebo group (p < 0.001 for both comparisons with placebo). Diarrhea and nausea were more frequent with resmetirom than with placebo. The incidence of serious adverse events was similar across trial groups: 10.9% in the 80-mg resmetirom group, 12.7% in the 100-mg resmetirom group, and 11.5% in the placebo group.

Conclusions: Both the 80-mg dose and the 100-mg dose of resmetirom were superior to placebo with respect to resolution of non-alcoholic steatohepatitis and improvement in liver fibrosis by at least 1 stage.

S.A. Harrison, M.D., Professor of Medicine, Pinnacle Clinical Research, San Antonio, TX, USA, E-Mail: sharrison@pinnacleresearch.com

DOI: 10.1056/nejmoa2309000

Back to overview

this could be of interest:

Adequate versus deep response to ursodeoxycholic acid in primary biliary cholangitis: To what extent and under what conditions is normal alkaline phosphatase level associated with complication-free survival gain?

Hepatology. 2024;79(1):39–48

Lack of complete biochemical response in autoimmune hepatitis leads to adverse outcome: First report of the IAIHG retrospective registry

Hepatology. 2024;79(3):538–50

More articles on the topic